Treatments/clinical outcomes in ER+ HER2-negative breast cancer (BC) where treatment decisions were recurrence score (RS)-guided: Analysis by histologic subtype.

Authors

null

Salomon M. Stemmer

Davidoff Cancer Center, Tel Aviv, Israel

Salomon M. Stemmer , Mariana Steiner , Shulamith Rizel , Noa Ben Baruch , David B Geffen , Lior Soussan-Gutman , Avital Bareket-Samish , Bella Nisenbaum , Kevin Isaacs , Georgeta Fried , Ora Rosengarten , Beatrice Uziely , Christer Svedman , Debbie McCullough , Shmuel Klang , Ella Evron , Natalya Karminsky , Hadassah Goldberg , Steven Shak , Nicky Liebermann

Organizations

Davidoff Cancer Center, Tel Aviv, Israel, Lin Medical Center, Haifa, Israel, Davidoff Cancer Center, Petah Tikva, Israel, Kaplan Medical Center, Rehovot, Israel, Soroka University Medical Center/Ben-Gurion University of the Negev, Beer Sheva, Israel, Teva Pharmaceutical Industries, Ltd., Shoham, Israel, BioInsight Ltd., Zichron Yaakov, Israel, Meir Medical Center, Kfar-Saba, Israel, Ha'emek Medical Center, Afula, Israel, Institute of Oncology, Rambam Health Care Campus, Haifa, Israel, Sha' are Zedek Medical Center, Jerusalem, Israel, Hadassah Hebrew University Medical Center, Jerusalem, Israel, Genomic Health, Redwood City, CA, Clalit Health Services, Tel Aviv, Israel, Assaf Harofeh Medical Center, Zerifin, Israel, Wolfson Medical Center, Holon, Israel, Galilee Medical Center, Nahariya, Israel

Research Funding

Pharmaceutical/Biotech Company

Background: The RS assay is widely used to guide treatment decisions in ER+ HER2-negative early BC regardless of tumor histology. However, the RS validation studies did not include an analysis by histologic subtype. We investigated treatments/clinical outcomes in RS-tested Clalit Health Services (CHS) patients (pts) by histologic subtype, focusing on invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). Methods: This exploratory analysis of the CHS cohort included BC pts with N0/N1mi/N1 disease who were RS-tested from 1/2006 through 12/2010 (N0) or 12/2011 (N1mi/N1). Data from medical records were analyzed to assess risks of distant recurrence and BC death by histologic subtype. Results: The cohort included 2510 pts: 2060 (82%) IDC, 298 (12%) ILC, and 152 (6%) unknown/others. Median follow up for IDC/ILC pts was 6.0/6.1 yrs. Median age in IDC/ILC pts was 60/62 yrs; median tumor size was 1.5/1.8 cm; 71%/71% were N0, and 29%/29% were N1mi/N1. RS distribution (<18, 18-30, ≥31) was 50%, 39%, and 11%, respectively for IDC pts and 48%, 48%, and 4%, respectively, for ILC pts. Chemotherapy (CT) use for each RS group was similar between IDC and ILC pts; 5-yr Kaplan-Meier estimates for the risk of distant recurrence and BC death differed significantly across RS groups in both IDC and ILC; clinical outcomes for IDC and ILC pts were similar within risk groups see Table. Conclusions: For both IDC and ILC pts, treatment was aligned with the RS results. Within each RS group, there was no difference in clinical outcomes between these histologic subtypes, however the number of pts with ILC and RS≥31 was limited.

RS<18
RS: 18-30
RS≥31
NCT use, %5-yr distant recurrence risk (95% CI)/
5-yr BC death risk
(95% CI)
NCT use, %5-yr distant recurrence risk (95% CI)/
5-yr BC death risk
(95% CI)
NCT use, %5-yr distant recurrence risk (95% CI)/
5-yr BC death risk
(95% CI)
P*
IDC102031.4 (0.8-2.4)804293.8 (2.7-5.5)2368611.2 (7.8-16.1)<.001
0.1 (0.0-0.7)1.6 (0.9-2.8)6.3 (3.7-10.4)<.001
ILC14330.7 (0.1-4.9)144244.4 (2.0-9.5)11829.1 (1.3-49.2).035
.004
0.0 (0.0-0.0)1.6 (0.4-6.3)9.1 (1.3-49.2)004

*Distant recurrence risk/BC death in RS groups was compared using Log-rank test.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2017 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: <span>Breast Cancer—Local/Regional/Adjuvant</span>

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Citation

J Clin Oncol 35, 2017 (suppl; abstr e12053)

DOI

10.1200/JCO.2017.35.15_suppl.e12053

Abstract #

e12053

Abstract Disclosures